About 2.1 billion people around the world do not have immediate access to clean drinking water.
The Water Abundance XPrize competition rewards innovators who come up with new ways to harvest clean water from the atmosphere.
This year, the winning design can produce at least 2,000 litres of water per day, which would satisfy the needs of 100 people.… See More.
Although the coronavirus vaccine is progressing at a breakneck pace, some people feel that it is not progressing fast enough. As such, they have volunteered in the One Day Sooner movement to get deliberately infected with the coronavirus in order to speed up vaccine development.
Discord Link: https://discord.gg/brYJDEr
Patreon link: https://www.patreon.com/TheFuturistTom
Please follow our instagram at: https://www.instagram.com/the_futurist_tom
For business inquires, please contact [email protected]
(Reuters) — Nearly a third of more than 40 large companies seeking U.S. bankruptcy protection during the coronavirus pandemic awarded bonuses to executives within a month of filing their cases, according to a Reuters analysis of securities filings and court records.
Under a 2005 bankruptcy law, companies are banned, with few exceptions, from paying executives retention bonuses while in bankruptcy. But the firms seized on a loophole by granting payouts before filing.
Six of the 14 companies that approved bonuses within a month of their filings cited business challenges executives faced during the pandemic in justifying the compensation.
Do you agree with these predictions?
The first few months of 2020 have radically reshaped the way we work and how the world gets things done. While the wide use of robotaxis or self-driving freight trucks isn’t yet in place, the Covid-19 pandemic has hurried the introduction of artificial intelligence across all industries. Whether through outbreak tracing or contactless customer pay interactions, the impact has been immediate, but it also provides a window into what’s to come. The second annual Forbes’ AI 50, which highlights the most promising U.S.-based artificial intelligence companies, features a group of founders who are already pondering what their space will look like in the future, though all agree that Covid-19 has permanently accelerated or altered the spread of AI.
“We have seen two years of digital transformation in the course of the last two months,” Abnormal Security CEO Evan Reiser told Forbes in May. As more parts of a company are forced to move online, Reiser expects to see AI being put to use to help businesses analyze the newly available data or to increase efficiency.
Tired of the coronavirus? Well, the good news is that there are several vaccines in development that are in their final phase of clinical testing before they can be approved for public usage. The bad thing, however, is the fact that there are only so many doses each vaccine manufacturer can make- meaning solving the pandemic will be as much a problem of distribution and manufacturing as it is research and development.
PS: The stock footage from this photo comes from Videvo!
Continue reading “Coronavirus Vaccines in Phase 3 Development | The State of Science” »
A ZDNet report, citing Samsung’s white paper, stated that the sector of the International Telecommunication Union (ITU) responsible for radio communication, ITU-R, is likely to commence their work to define a 6G vision in 2021.
The 3G took 15 years to be defined, while the time taken for the 5G was eight years.
Samsung last year also asserted that it would continue to invest and pre-study future business, including the sixth generation mobile network, reported GizChina.
The global health crisis is accelerating meta-trends and hurling civilization towards the transhuman future. The disruptors are being disrupted, and the rush is on to digitize and virtualize everything in weeks’ time that otherwise would have taken a few years to play out. Recent surveys show that we have compressed five years in business and consumer digital adoption within a couple of months. https://www.ecstadelic.net/top-stories/the-great-reset-2020-…-look-like
#GreatReset2020
Continue reading “The Great Reset 2020: What Would the Near Future Post-Pandemic World Look Like?” »
No industry will be spared.
The pharmaceutical business is perhaps the only industry on the planet, where to get the product from idea to market the company needs to spend about a decade, several billion dollars, and there is about 90% chance of failure. It is very different from the IT business, where only the paranoid survive but a business where executives need to plan decades ahead and execute. So when the revolution in artificial intelligence fueled by credible advances in deep learning hit in 2013–2014, the pharmaceutical industry executives got interested but did not immediately jump on the bandwagon. Many pharmaceutical companies started investing heavily in internal data science R&D but without a coordinated strategy it looked more like re-branding exercise with the many heads of data science, digital, and AI in one organization and often in one department. And while some of the pharmaceutical companies invested in AI startups no sizable acquisitions were made to date. Most discussions with AI startups started with “show me a clinical asset in Phase III where you identified a target and generated a molecule using AI?” or “how are you different from a myriad of other AI startups?” often coming from the newly-minted heads of data science strategy who, in theory, need to know the market.
However, some of the pharmaceutical companies managed to demonstrate very impressive results in the individual segments of drug discovery and development. For example, around 2018 AstraZeneca started publishing in generative chemistry and by 2019 published several impressive papers that were noticed by the community. Several other pharmaceutical companies demonstrated impressive internal modules and Eli Lilly built an impressive AI-powered robotics lab in cooperation with a startup.
Regeneron rose as much as 2.4% in the stock market today, touching a record high of 655.93. Shares seesawed in a small range Thursday before ending the day up a small fraction, at 640.63. The peak price topped Regeneron stock’s previous high of 653.53, touched on Tuesday. Regeneron is part of the IBD Biomed/Biotech group, which ranks No. 14 out of 197 industry groups tracked. The group is just off its all-time high, which it hit on June 23.
Regeneron Pharmaceuticals (REGN) jumped to an all-time high Thursday, its second of the week, as analysts remain bullish on Regeneron stock due to its coronavirus treatment and other businesses.
